Literature DB >> 15606376

Advances in the management of hereditary medullary thyroid cancer.

A Machens1, J Ukkat, M Brauckhoff, O Gimm, H Dralle.   

Abstract

This work draws on recent advances during the era of codon-oriented prophylactic surgery for hereditary medullary thyroid cancer (MTC). Milestones included identification of RET (REarranged during Transfection) as the susceptibility gene, introduction of prophylactic surgery on evidence of a RET germline mutation, revelation of genotype-phenotype correlations within the MEN 2 spectrum and demonstration of age-related progression of MTC. Novel surgical techniques, notably systemic microdissection and compartment-oriented surgery, have greatly enhanced surgical cure. Uncovering molecular pathways from RET genotype to MEN 2 phenotype should provide treatment options for RET mutation carriers whose MTC currently is too advanced for cure.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15606376     DOI: 10.1111/j.1365-2796.2004.01423.x

Source DB:  PubMed          Journal:  J Intern Med        ISSN: 0954-6820            Impact factor:   8.989


  18 in total

Review 1.  Medullary thyroid cancer: monitoring and therapy.

Authors:  Douglas W Ball
Journal:  Endocrinol Metab Clin North Am       Date:  2007-09       Impact factor: 4.741

2.  [Prophylactic thyroid surgery].

Authors:  A Frilling; F Weber
Journal:  Chirurg       Date:  2006-01       Impact factor: 0.955

Review 3.  Multiple endocrine neoplasia syndromes, children, Hirschsprung's disease and RET.

Authors:  S W Moore; M G Zaahl
Journal:  Pediatr Surg Int       Date:  2008-03-26       Impact factor: 1.827

Review 4.  Revised American Thyroid Association guidelines for the management of medullary thyroid carcinoma.

Authors:  Samuel A Wells; Sylvia L Asa; Henning Dralle; Rossella Elisei; Douglas B Evans; Robert F Gagel; Nancy Lee; Andreas Machens; Jeffrey F Moley; Furio Pacini; Friedhelm Raue; Karin Frank-Raue; Bruce Robinson; M Sara Rosenthal; Massimo Santoro; Martin Schlumberger; Manisha Shah; Steven G Waguespack
Journal:  Thyroid       Date:  2015-06       Impact factor: 6.568

5.  [Hereditary neuroendrocrine tumors. Multiple endocrine neoplasia type 1 and 2].

Authors:  A Rinke; S R Galan; V Fendrich; P H Kann; D K Bartsch; T M Gress
Journal:  Internist (Berl)       Date:  2012-04       Impact factor: 0.743

6.  Role of preoperative basal calcitonin levels in the timing of prophylactic thyroidectomy in patients with germline RET mutations.

Authors:  Jean-Christophe Lifante; Claire Blanchard; Eric Mirallié; Albert David; Jean-Louis Peix
Journal:  World J Surg       Date:  2014-03       Impact factor: 3.352

Review 7.  Genotype-phenotype based surgical concept of hereditary medullary thyroid carcinoma.

Authors:  Andreas Machens; Henning Dralle
Journal:  World J Surg       Date:  2007-05       Impact factor: 3.352

8.  Characterization of the largest kindred with MEN2A due to a Cys609Ser RET mutation.

Authors:  Caterina Mian; Susi Barollo; Laura Zambonin; Gianmaria Pennelli; Paolo Bernante; Maria Rosa Pelizzo; Davide Nacamulli; Franco Mantero; Maria Elisa Girelli; Giuseppe Opocher
Journal:  Fam Cancer       Date:  2009-05-28       Impact factor: 2.375

9.  Prognostic influence of clinical and pathological factors in medullary thyroid carcinoma: a study of 53 cases.

Authors:  Lenine G Brandão; Beatriz G Cavalheiro; Consuelo R Junqueira
Journal:  Clinics (Sao Paulo)       Date:  2009       Impact factor: 2.365

10.  Factors predicting outcome of total thyroidectomy in young patients with multiple endocrine neoplasia type 2: a nationwide long-term follow-up study.

Authors:  Jennifer M J Schreinemakers; Menno R Vriens; Gerlof D Valk; Jan-Willem B de Groot; John T Plukker; Klaas M A Bax; Jaap F Hamming; Rob B van der Luijt; Daniel C Aronson; Inne H M Borel Rinkes
Journal:  World J Surg       Date:  2010-04       Impact factor: 3.352

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.